Axsome Therapeutics (AXSM) Total Non-Current Liabilities (2017 - 2026)

Axsome Therapeutics (AXSM) has 9 years of Total Non-Current Liabilities data on file, last reported at $585.3 million in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities rose 29.24% year-over-year to $585.3 million; the trailing twelve-month figure through Mar 2026 stood at $585.3 million (up 29.24% YoY), and the FY2025 full-year result was $524.0 million, up 24.81% from the prior year.
• Total Non-Current Liabilities grew to $585.3 million in Q1 2026, from $524.0 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $585.3 million in Q1 2026 to a low of $136.0 million in Q2 2022.
• A 5-year average of $357.5 million and a median of $353.7 million in 2024 frame the typical range for Total Non-Current Liabilities.
• Across the five-year window, Total Non-Current Liabilities surged 120.05% in 2023 and gained 24.81% in 2025, its largest moves.
• Tracing AXSM's Total Non-Current Liabilities over 5 years: stood at $190.8 million in 2022, then surged by 69.77% to $324.0 million in 2023, then grew by 29.59% to $419.8 million in 2024, then grew by 24.81% to $524.0 million in 2025, then gained by 11.7% to $585.3 million in 2026.
• Business Quant data shows AXSM's Total Non-Current Liabilities at $585.3 million in Q1 2026, $524.0 million in Q4 2025, and $505.7 million in Q3 2025.